Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Free Cash Flow history runs 14 years deep, the most recent figure standing at -$119.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 29.05% year-over-year to -$119.7 million; the TTM figure through Mar 2026 stood at -$303.8 million (down 8.37% YoY), while the FY2025 annual figure was -$276.9 million, down 18.92% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$119.7 million, down from -$24.0 million in the prior quarter.
• The five-year high for Free Cash Flow was -$17.9 million in Q2 2022, with the low at -$119.7 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$45.5 million (2023), against an average of -$53.5 million.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 192.58% in 2023, then surged 67.33% in 2025.
• Viridian Therapeutics, Inc.\DE's Free Cash Flow stood at -$33.9 million in 2022, then decreased by 12.38% to -$38.0 million in 2023, then sank by 93.04% to -$73.4 million in 2024, then soared by 67.33% to -$24.0 million in 2025, then sank by 398.78% to -$119.7 million in 2026.
• Business Quant data shows VRDN's Free Cash Flow at -$119.7 million in Q1 2026, -$24.0 million in Q4 2025, and -$84.7 million in Q3 2025.